GBIO Logo

Generation Bio Co. (GBIO) 

NASDAQ
Market Cap
$160.17M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
121 of 776
Rank in Industry
82 of 433

Largest Insider Buys in Sector

GBIO Stock Price History Chart

GBIO Stock Performance

About Generation Bio Co.

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Insider Activity of Generation Bio Co.

Over the last 12 months, insiders at Generation Bio Co. have bought $778,895 and sold $26,332 worth of Generation Bio Co. stock.

On average, over the past 5 years, insiders at Generation Bio Co. have bought $34.75M and sold $18.42M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Rowland Charles A Jr (director) — $1.43M. Nicholson Donald William (director) — $144,000. Quinn Anthony G. (director) — $124,778.

The last purchase of 8,000 shares for transaction amount of $14,339 was made by Appelhans Dannielle (director) on 2023‑12‑08.

List of Insider Buy and Sell Transactions, Generation Bio Co.

2024-07-01SaleCHIEF OPERATING OFFICER
6,719
0.0099%
$2.74$18,4100.00%
2024-01-02SaleCHIEF STRATEGY OFFICER
2,445
0.0032%
$1.62$3,961+47.71%
2024-01-02SaleCHIEF OPERATING OFFICER
2,445
0.0032%
$1.62$3,961+47.71%
2023-12-08Purchasedirector
8,000
0.0127%
$1.79$14,339+54.84%
2023-12-04Purchasedirector
150,000
0.2255%
$1.50$225,000+74.00%
2023-12-04Purchasedirector
12,000
0.018%
$1.50$18,000+74.00%
2023-12-01Purchasedirector
192,960
0.2723%
$1.31$252,778+81.82%
2023-12-01Purchasedirector
100,000
0.1551%
$1.44$144,000+81.82%
2023-12-01Purchasedirector
88,495
0.1344%
$1.41$124,778+81.82%
2023-08-23SaleCHIEF OPERATING OFFICER
3,116
0.0046%
$4.93$15,362-43.73%
2023-07-03SaleCHIEF STRATEGY OFFICER
3,116
0.0054%
$5.29$16,484-40.51%
2023-04-25SaleCHIEF OPERATING OFFICER
2,914
0.0049%
$4.61$13,434-27.77%
2023-01-26SaleCHIEF OPERATING OFFICER
2,695
0.0044%
$5.56$14,984-26.23%
2023-01-10SaleCHIEF OPERATING OFFICER
1,865
0.003%
$4.57$8,523-9.01%
2023-01-09SaleCHIEF STRATEGY OFFICER
1,865
0.0035%
$5.11$9,530-6.05%
2022-10-27SaleCHIEF OPERATING OFFICER
2,914
0.0051%
$5.03$14,657-5.45%
2022-09-29SaleCHIEF OPERATING OFFICER
2,828
0.0049%
$5.24$14,819-5.50%
2022-03-09Purchase
8,126
0.0137%
$4.71$38,273+14.72%
2021-09-29Saledirector
16,586
0.0297%
$24.59$407,850-72.60%
2021-09-29Sale10 percent owner
16,586
0.0297%
$24.59$407,850-72.60%

Insider Historical Profitability

33.7%
Rowland Charles A Jrdirector
534757
0.8012%
$2.4040+21.36%
Nicholson Donald Williamdirector
213576
0.32%
$2.4030+5.04%
Quinn Anthony G.director
88495
0.1326%
$2.4010
Appelhans Dannielledirector
12637
0.0189%
$2.4020
Invus Public Equities, L.P.10 percent owner
2814191
4.2166%
$2.4010+47.36%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
T. Rowe Price$36.14M13.358.88M+28.19%+$7.95M<0.01
Atlas Venture Life Science Advisors Llc$33.7M12.458.28M0%+$03.13
Fidelity Investments$21.71M8.025.33M-0.34%-$73,829.80<0.01
Bellevue Group$15.72M5.83.86M+6.76%+$995,094.630.24
BlackRock$12.41M4.583.05M-3.77%-$486,633.64<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.